This Cutaquig market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to the rising prevalence of primary and secondary immunodeficiency disorders, increased patient preference for home-based treatments, higher adoption of subcutaneous immunoglobulin (SCIG), improvements in healthcare infrastructure, greater awareness of immunodeficiency conditions, and the growing incidence of autoimmune diseases.
Future market growth can be attributed to factors such as increased awareness of subcutaneous immunoglobulin therapies, expanded healthcare access in emerging markets, the rising prevalence of immunodeficiency disorders, a growing elderly population, supportive regulatory approvals for innovative therapies, and strategic partnerships to improve product availability worldwide. Key trends during the forecast period include advancements in home-based SCIG delivery systems, improved vial designs for dose customization, integration of digital health monitoring, innovations in plasma-derived product manufacturing, and enhanced formulations for better tolerability.
The growing prevalence of immunodeficiency diseases is expected to drive the expansion of the cutaquig market. Immunodeficiency diseases are conditions where the immune system's ability to combat infections and diseases is impaired or completely absent, often due to genetic factors, underlying health conditions, or external influences such as medications or infections. The rise in immunodeficiency diseases is attributed to genetic factors, aging populations, environmental pollution, unhealthy lifestyles, increasing chronic illnesses, and better diagnostic capabilities leading to improved detection rates. Cutaquig, a subcutaneous immunoglobulin (SCIG), is used to treat primary immunodeficiency diseases by providing antibody replacement therapy to enhance immune function and reduce infection risk. For example, in 2023, the Immune Deficiency Foundation (IDF), a US-based non-profit organization, reported that 1,177 patients were living with primary immunodeficiency (PI), with common variable immunodeficiency (CVID) being the most common diagnosis, affecting 62% of them. Thus, the rise in immunodeficiency diseases is contributing to the growth of the cutaquig market.
The increasing prevalence of infectious diseases is also expected to drive the cutaquig market’s growth. Infectious diseases are caused by microorganisms such as bacteria, viruses, fungi, or parasites. These diseases are on the rise due to factors such as global travel, urbanization, deforestation, climate change, drug resistance, and population growth. Cutaquig is used to provide antibody support for patients with weakened immune systems, helping to reduce the frequency and severity of infections. For instance, in 2024, Health Equity Matters, an Australia-based nonprofit organization, reported a 3.9% increase in the number of people living with HIV, from 28,870 at the end of 2022 to 30,010 at the end of 2023. Therefore, the rising prevalence of infectious diseases will further drive the growth of the cutaquig market.
The increasing geriatric population is expected to further boost the cutaquig market. The geriatric population, referring to individuals aged 65 and older, experiences age-related changes such as reduced skin elasticity, wrinkles, and fine lines. The growth of the geriatric population is driven by factors such as advancements in healthcare, improved living standards, and medical innovations that have led to longer life expectancies. Cutaquig is used within this demographic to manage immunodeficiencies by enhancing immune function and reducing the risk of infections. For example, in October 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that by 2030, one in six people worldwide would be aged 60 or older. This population is expected to reach 1.4 billion by 2030, up from 1 billion in 2020, and is predicted to double to 2.1 billion by 2050. As a result, the growing geriatric population is contributing to the expansion of the cutaquig market.
The key company operating in the cutaquig market is Octapharma AG.
North America was the largest region in the cutaquig market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cutaquig report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cutaquig market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cutaquig is a subcutaneous immunoglobulin (SCIG) treatment used to manage primary immunodeficiency (PI), a group of disorders that weaken the immune system. It provides antibodies to enhance immunity and protect against infections. Cutaquig offers a convenient home-based treatment option for individuals with chronic immune deficiencies.
The primary indication of cutaquig are common variable immunodeficiency (CVID), x-linked agammaglobulinemia, and severe combined immunodeficiency (SCID). Common Variable Immunodeficiency (CVID) is a primary immune disorder characterized by low antibody levels, leaving individuals more susceptible to infections. Symptoms often include frequent bacterial infections, especially in the respiratory and gastrointestinal systems. Cutaquig is distributed through hospital pharmacies, specialty pharmacies, and home healthcare providers, and is used in clinics, homecare settings, hospitals, and other healthcare environments.
The cutaquig market research report is one of a series of new reports that provides cutaquig market statistics, including cutaquig industry global market size, regional shares, competitors with a cutaquig market share, detailed cutaquig market segments, market trends and opportunities, and any further data you may need to thrive in the cutaquig industry. This cutaquig market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cutaquig market consists of sales of infusion pumps, needle kits, syringes and connectors, and immunoglobulin (IgG) therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to the rising prevalence of primary and secondary immunodeficiency disorders, increased patient preference for home-based treatments, higher adoption of subcutaneous immunoglobulin (SCIG), improvements in healthcare infrastructure, greater awareness of immunodeficiency conditions, and the growing incidence of autoimmune diseases.
Future market growth can be attributed to factors such as increased awareness of subcutaneous immunoglobulin therapies, expanded healthcare access in emerging markets, the rising prevalence of immunodeficiency disorders, a growing elderly population, supportive regulatory approvals for innovative therapies, and strategic partnerships to improve product availability worldwide. Key trends during the forecast period include advancements in home-based SCIG delivery systems, improved vial designs for dose customization, integration of digital health monitoring, innovations in plasma-derived product manufacturing, and enhanced formulations for better tolerability.
The growing prevalence of immunodeficiency diseases is expected to drive the expansion of the cutaquig market. Immunodeficiency diseases are conditions where the immune system's ability to combat infections and diseases is impaired or completely absent, often due to genetic factors, underlying health conditions, or external influences such as medications or infections. The rise in immunodeficiency diseases is attributed to genetic factors, aging populations, environmental pollution, unhealthy lifestyles, increasing chronic illnesses, and better diagnostic capabilities leading to improved detection rates. Cutaquig, a subcutaneous immunoglobulin (SCIG), is used to treat primary immunodeficiency diseases by providing antibody replacement therapy to enhance immune function and reduce infection risk. For example, in 2023, the Immune Deficiency Foundation (IDF), a US-based non-profit organization, reported that 1,177 patients were living with primary immunodeficiency (PI), with common variable immunodeficiency (CVID) being the most common diagnosis, affecting 62% of them. Thus, the rise in immunodeficiency diseases is contributing to the growth of the cutaquig market.
The increasing prevalence of infectious diseases is also expected to drive the cutaquig market’s growth. Infectious diseases are caused by microorganisms such as bacteria, viruses, fungi, or parasites. These diseases are on the rise due to factors such as global travel, urbanization, deforestation, climate change, drug resistance, and population growth. Cutaquig is used to provide antibody support for patients with weakened immune systems, helping to reduce the frequency and severity of infections. For instance, in 2024, Health Equity Matters, an Australia-based nonprofit organization, reported a 3.9% increase in the number of people living with HIV, from 28,870 at the end of 2022 to 30,010 at the end of 2023. Therefore, the rising prevalence of infectious diseases will further drive the growth of the cutaquig market.
The increasing geriatric population is expected to further boost the cutaquig market. The geriatric population, referring to individuals aged 65 and older, experiences age-related changes such as reduced skin elasticity, wrinkles, and fine lines. The growth of the geriatric population is driven by factors such as advancements in healthcare, improved living standards, and medical innovations that have led to longer life expectancies. Cutaquig is used within this demographic to manage immunodeficiencies by enhancing immune function and reducing the risk of infections. For example, in October 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that by 2030, one in six people worldwide would be aged 60 or older. This population is expected to reach 1.4 billion by 2030, up from 1 billion in 2020, and is predicted to double to 2.1 billion by 2050. As a result, the growing geriatric population is contributing to the expansion of the cutaquig market.
The key company operating in the cutaquig market is Octapharma AG.
North America was the largest region in the cutaquig market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cutaquig report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cutaquig market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cutaquig is a subcutaneous immunoglobulin (SCIG) treatment used to manage primary immunodeficiency (PI), a group of disorders that weaken the immune system. It provides antibodies to enhance immunity and protect against infections. Cutaquig offers a convenient home-based treatment option for individuals with chronic immune deficiencies.
The primary indication of cutaquig are common variable immunodeficiency (CVID), x-linked agammaglobulinemia, and severe combined immunodeficiency (SCID). Common Variable Immunodeficiency (CVID) is a primary immune disorder characterized by low antibody levels, leaving individuals more susceptible to infections. Symptoms often include frequent bacterial infections, especially in the respiratory and gastrointestinal systems. Cutaquig is distributed through hospital pharmacies, specialty pharmacies, and home healthcare providers, and is used in clinics, homecare settings, hospitals, and other healthcare environments.
The cutaquig market research report is one of a series of new reports that provides cutaquig market statistics, including cutaquig industry global market size, regional shares, competitors with a cutaquig market share, detailed cutaquig market segments, market trends and opportunities, and any further data you may need to thrive in the cutaquig industry. This cutaquig market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cutaquig market consists of sales of infusion pumps, needle kits, syringes and connectors, and immunoglobulin (IgG) therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cutaquig Market Characteristics4. Cutaquig Market Trends and Strategies5. Cutaquig Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Cutaquig Pricing Analysis & Forecasts30. Global Cutaquig Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Cutaquig Market32. Recent Developments in the Cutaquig Market
3. Cutaquig Market Biologic Drug Characteristics
6. Global Cutaquig Growth Analysis and Strategic Analysis Framework
8. Cutaquig Market Segmentation
9. Global Cutaquig Epidemiology of Clinical Indications
10. Cutaquig Market Regional and Country Analysis
11. Asia-Pacific Cutaquig Market
12. China Cutaquig Market
13. India Cutaquig Market
14. Japan Cutaquig Market
15. Australia Cutaquig Market
16. South Korea Cutaquig Market
17. Western Europe Cutaquig Market
18. UK Cutaquig Market
19. Germany Cutaquig Market
20. France Cutaquig Market
21. Eastern Europe Cutaquig Market
22. North America Cutaquig Market
23. USA Cutaquig Market
24. Canada Cutaquig Market
25. South America Cutaquig Market
26. Middle East Cutaquig Market
27. Africa Cutaquig Market
28. Cutaquig Market Competitive Landscape and Company Profiles
29. Global Cutaquig Market Pipeline Analysis
33. Cutaquig Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Cutaquig Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cutaquig market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cutaquig? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cutaquig market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Common Variable Immunodeficiency (CVID); X-Linked Agammaglobulinemia; Severe Combined Immunodeficiency (SCID)2) by Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Home Healthcare Providers
3) by End-Use: Clinics; Homecare; Hospitals; Other End-Uses
Key Companies Mentioned:Octapharma AG
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Octapharma AG
